ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

ERYTECH Pharma S.A.

PHAXIAM Therapeutics develops antibacterial treatments based on the use of bacteriophage viruses to combat bacterial infections, particularly those resistant to antibiotics. The company addresses antimicrobial resistance, which is a major global health issue.

Metric
Company Name	ERYTECH Pharma S.A.
Symbol	ERYP
MSH ID	COM:ERYTECH
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	FR
Stage
Employee Count	49
Website	erytech.com
LinkedIn
Founders

Metric
Market Cap	51.40M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-297.86K
EBITDA	-25.15M
Operating Income	-26.85M
Net Income	-24.81M
EPS	-4.88
Diluted EPS	-4.88
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.61
Operating Profit Margin
EBITDA Margin	-17.96
Net Profit Margin
Return on Equity	0.03
Return on Assets	0.02
Return on Capital Employed	-0.08

COM:ERYTECH

PHAXIAM Therapeutics

Last Close

0.80

28/06 15:35

Market Cap

48.66M

Beta: -

Volume Today

27.49K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	40.46
P/B Ratio	1.06
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	15.77
EV Multiple	47.91

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	411.55
Operating Cycle	1.50K
Cash Conversion Cycle
Asset Turnover	0.05

Metric
Operating Cash Flow	-25.74M
Free Cash Flow	-25.97M
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents	11.06M
Accounts Receivable	230.26K
Inventory
Goodwill	10.16M
Debt to Capitalization	0.41
Debt to Assets	0.30
Current Ratio	3.65
Quick Ratio	3.54

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue